StockData
HCW Biologics Inc. logo

HCW Biologics Inc. (HCWB) shareholders

HCWBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3095% below fair value
$0.76−0.01 (-1.65%)

Close on Nov 18, 2026Market cap $1.40MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
5.6%
0M of 2M shares
Institutional holders
12
3 new, 6 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
6 buys · 0 sales
Net bought $531.72K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Hing C. Wong, Ph.D.501,91123.38%13D (active) amendmentMay 15, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of HCWBValueChange% of portfolio
Jane Street Group, LLC52,1382.84%$260.17K+49,7820.00%
Citadel Advisors LLC19,9421.09%$99.51K+15,5950.00%
Hrt Financial LP13,5830.74%$67.00K−30,8160.00%
Vanguard Fiduciary Trust Co6,5100.35%$32.49K+6,1930.00%
Tower Research Capital LLC (TRC)4,1170.22%$20.54K+1,6430.00%
Connective Capital Management, LLC3,3380.18%$16.66KNew0.01%
Vanguard Capital Management LLC2,0030.11%$10.00K−10.00%
Golden State Wealth Management, LLC1,6670.09%$8.32K–0.00%
Barclays PLC1910.01%$953New0.00%
Caitong International Asset Management Co., Ltd110.00%$10New0.00%
Osaic Holdings, Inc.40.00%$20–0.00%
UBS Group AG10.00%$5−1,5360.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026120M5.6%3 / 43 / 60M0M
Q1 2026150M4.1%7 / 50 / 50M0M
Q4 2025140M4.0%5 / 23 / 10M0M
Q3 2025100M1.1%4 / 11 / 20M0M
Q2 202580M0.2%8 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

4 funds held HCWB in Q2 2026, 27% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of HCWBValue% of fundAs of
Vanguard Extended Market Index Fund2,0040.11%$10.00K0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Hing C. WongChief Executive Officer, Director, 10% owner125,8456.85%Jul 31, 2026
Lee FlowersSVP of Business Development8,6910.47%Jul 31, 2026
Rebecca ByamChief Financial Officer57,2453.12%May 27, 2026
Scott T. GarrettDirector67,1493.66%Jul 31, 2026
Gary M. WinerDirector4,0750.22%May 20, 2025
Rick S. GreeneDirector2,0660.11%May 9, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Lee Flowers
SVP of Business Development
Jul 29, 2026Buy+7,736$2.59$20.04K8,691
Hing C. Wong
Chief Executive Officer, Director, 10% owner
Jul 29, 2026Buy+23,210$2.59$60.11K125,845
Scott T. Garrett
Director
Jul 29, 2026Buy+7,736$2.59$20.04K41,644
Scott T. Garrett
Director
May 22, 2026Buy+177,936$1.41$250.89K203,441
Hing C. Wong
Chief Executive Officer, Director, 10% owner
May 22, 2026Buy+113,879$1.41$160.57K615,790
Rebecca Byam
Chief Financial Officer
May 22, 2026Buy+14,235$1.41$20.07K57,245
Gary M. Winer
Director
May 16, 2025Buy+1,342$7.45$10.00K4,075
Hing C. Wong
Chief Executive Officer, Director, 10% owner
May 16, 2025Buy+8,054$7.45$60.00K501,911
Scott T. Garrett
Director
May 16, 2025Buy+13,423$7.45$100.00K25,505
Rebecca Byam
Chief Financial Officer
May 8, 2025Buy+8,462$26.00$220.01K43,010
Scott T. Garrett
Director
May 8, 2025Buy+5,385$26.00$140.01K12,082
Hing C. Wong
Chief Executive Officer, Director, 10% owner
May 8, 2025Buy+92,500$26.00$2.41M493,857
Gary M. Winer
Director
May 8, 2025Buy+2,308$26.00$60.01K2,733
Lee Flowers
SVP of Business Development
May 8, 2025Buy+962$26.00$25.01K5,720
Rick S. Greene
Director
May 8, 2025Buy+962$26.00$25.01K2,066
Hing C. Wong
Chief Executive Officer, Director
Feb 20, 2024Award+739,288$1.40$1.04M16,054,156
Rick S. Greene
Director
Feb 20, 2024Award+35,714$1.40$50.00K44,125
Scott T. Garrett
Director
Feb 20, 2024Award+142,858$1.40$200.00K267,858
Rebecca Byam
Chief Financial Officer
Feb 20, 2024Award+760,714$1.40$1.06M1,381,909
Lee Flowers
SVP of Business Development
Feb 20, 2024Award+71,429$1.40$100.00K190,238
Lisa M. Giles
Director
Feb 20, 2024Award+35,715$1.40$50.00K35,815
Peter Rhode
See Remarks
Dec 11, 2023Option exercise+14,000$0.14$1.96K77,500
Lee Flowers
SVP of Business Development
Dec 8, 2023Option exercise+7,501$0.14$1.05K118,809
Peter Rhode
See Remarks
Nov 17, 2023Option exercise+15,000$0.14$2.10K63,500
Rebecca Byam
Chief Financial Officer
Oct 19, 2023Option exercise+47,249$0.14$6.61K621,195
Hing C. Wong
Chief Executive Officer, Director
Sep 14, 2023Buy+1,800$2.08$3.74K15,314,868
Gary M. Winer
Director
Sep 14, 2023Buy+162$2.08$33716,121
Gary M. Winer
Director
Sep 14, 2023Buy+879$2.05$1.80K17,000
Gary M. Winer
Director
Sep 13, 2023Buy+46$2.00$9215,959
Gary M. Winer
Director
Sep 13, 2023Buy+500$2.05$1.03K15,913
Rebecca Byam
Chief Financial Officer
Sep 13, 2023Buy+5,000$2.10$10.50K573,946
Rebecca Byam
Chief Financial Officer
Sep 12, 2023Buy+5,000$2.09$10.45K568,946
Gary M. Winer
Director
Sep 12, 2023Buy+500$2.05$1.03K15,413
Rebecca Byam
Chief Financial Officer
Sep 11, 2023Buy+5,000$2.05$10.25K563,946
Gary M. Winer
Director
Sep 11, 2023Buy+99$2.05$20314,913
Gary M. Winer
Director
Sep 8, 2023Buy+1$1.90$214,814
Rebecca Byam
Chief Financial Officer
Sep 8, 2023Buy+5,000$2.02$10.10K558,946
Rebecca Byam
Chief Financial Officer
Sep 7, 2023Buy+5,000$1.95$9.75K553,946
Gary M. Winer
Director
Sep 7, 2023Buy+63$1.95$12314,813
Rebecca Byam
Chief Financial Officer
Sep 6, 2023Buy+5,000$1.95$9.75K548,946
Gary M. Winer
Director
Sep 5, 2023Buy+400$1.75$70014,750
Rebecca Byam
Chief Financial Officer
Jun 9, 2023Buy+20,000$2.06$41.20K543,946
Lee Flowers
SVP of Business Development
Jun 8, 2023Option exercise+5,356$0.14$750101,308
Lee Flowers
SVP of Business Development
Jun 8, 2023Buy+10,000$2.16$21.60K111,308
Rebecca Byam
Chief Financial Officer
Jun 8, 2023Buy+4,696$2.21$10.38K523,946
Rebecca Byam
Chief Financial Officer
Jun 7, 2023Buy+20,000$2.03$40.60K519,250
Rebecca Byam
Chief Financial Officer
Jun 6, 2023Buy+19,062$1.82$34.69K499,250
Rebecca Byam
Chief Financial Officer
Jun 5, 2023Buy+20,000$1.67$33.40K480,188
Hing C. Wong
Chief Executive Officer, Director
Jun 2, 2023Buy+800$1.54$1.23K15,313,068
Hing C. Wong
Chief Executive Officer, Director
Jun 1, 2023Buy+800$1.62$1.30K15,312,268
Gary M. Winer
Director
May 31, 2023Buy+500$1.50$75014,350
Hing C. Wong
Chief Executive Officer, Director
May 31, 2023Buy+2,000$1.55$3.10K15,311,468
Gary M. Winer
Director
May 30, 2023Buy+850$1.52$1.29K13,850
Hing C. Wong
Chief Executive Officer, Director
May 30, 2023Buy+3,000$1.55$4.65K15,309,468
Rebecca Byam
Chief Financial Officer
May 26, 2023Buy+20,000$1.66$33.20K460,188
Rebecca Byam
Chief Financial Officer
May 25, 2023Buy+20,000$1.62$32.40K440,188
Rebecca Byam
Chief Financial Officer
May 24, 2023Buy+20,000$1.61$32.20K420,188
Rebecca Byam
Chief Financial Officer
May 23, 2023Buy+5,036$1.57$7.91K400,188
Rebecca Byam
Chief Financial Officer
May 22, 2023Buy+33,450$1.53$51.18K395,152
Rebecca Byam
Chief Financial Officer
Nov 2, 2022Option exercise+33,750$0.14$4.73K361,702

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
4.12%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
+30.7%
From 0M shares
Short volume, 20 days
46.9%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of HCW Biologics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 86,085 shares on Sep 25, 2026 over the last 90 days.

See a number that looks wrong?